Lemborexant - Revision history

MDElliottMD: Category taxonomy ship: retag Sedative-Hypnotics -> Sedative-hypnotics

2026-05-22T00:36:48Z

Category taxonomy ship: retag Sedative-Hypnotics -> Sedative-hypnotics

← Older revision		Revision as of 00:36, 22 May 2026
Line 23:		Line 23:

	[[Category:Orexin Receptor Antagonists]]		[[Category:Orexin Receptor Antagonists]]
	[[Category:Sedative-~~Hypnotics~~]]		[[Category:Sedative-hypnotics]]
	[[Category:Hypnotics]]		[[Category:Hypnotics]]

MDElliottMD: Tier 2 taxonomy consolidation: remove retired Category:Anxiolytics & Sedative-Hypnotics

2026-05-21T17:44:49Z

Tier 2 taxonomy consolidation: remove retired Category:Anxiolytics & Sedative-Hypnotics

← Older revision		Revision as of 17:44, 21 May 2026
Line 22:		Line 22:
	}}		}}

	~~[[Category:Anxiolytics & Sedative-Hypnotics]]~~
	[[Category:Orexin Receptor Antagonists]]		[[Category:Orexin Receptor Antagonists]]
	[[Category:Sedative-Hypnotics]]		[[Category:Sedative-Hypnotics]]
	[[Category:Hypnotics]]		[[Category:Hypnotics]]

MDElliottMD: Tier 1 taxonomy consolidation: removed redundant Category:Orexin Antagonists (canonical already present)

2026-05-21T17:01:56Z

Tier 1 taxonomy consolidation: removed redundant Category:Orexin Antagonists (canonical already present)

← Older revision		Revision as of 17:01, 21 May 2026
Line 26:		Line 26:
	[[Category:Sedative-Hypnotics]]		[[Category:Sedative-Hypnotics]]
	[[Category:Hypnotics]]		[[Category:Hypnotics]]
	~~[[Category:Orexin Antagonists]]~~

MDElliottMD: Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

2026-05-19T03:16:08Z

Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

← Older revision		Revision as of 03:16, 19 May 2026
Line 14:		Line 14:
	\| pregnancy = Limited data; avoid		\| pregnancy = Limited data; avoid
	\| legal = Rx, Schedule IV (US)		\| legal = Rx, Schedule IV (US)
	\| intro = '''Lemborexant''' (brand name Dayvigo) is a dual orexin receptor antagonist (DORA) FDA-approved in December 2019 for insomnia in adults. Among DORAs, lemborexant has faster receptor association/dissociation kinetics than suvorexant — which is hypothesized to facilitate sleep onset while still maintaining adequate duration of antagonism for sleep maintenance. The 17-19 hour half-life can produce some next-day residual sedation in sensitive individuals.		\| intro = '''Lemborexant''' (brand name Dayvigo) is a dual orexin receptor antagonist (DORA) FDA-approved in December 2019 for insomnia in adults. Among DORAs, lemborexant has faster receptor association/dissociation kinetics than suvorexant, which is hypothesized to facilitate sleep onset while still maintaining adequate duration of antagonism for sleep maintenance. The 17-19 hour half-life can produce some next-day residual sedation in sensitive individuals.

	DORAs broadly produce sleep that more closely resembles physiologic sleep architecture than GABAergic hypnotics, with reduced REM suppression. Side effect profile favorable compared to benzodiazepines, but sleep paralysis, sleep-related hallucinations, and complex sleep behaviors have been reported.		DORAs broadly produce sleep that more closely resembles physiologic sleep architecture than GABAergic hypnotics, with reduced REM suppression. Side effect profile favorable compared to benzodiazepines, but sleep paralysis, sleep-related hallucinations, and complex sleep behaviors have been reported.

Maintenance script: Expand Lemborexant with Stahl-sourced detail (with skepticism)

2026-05-16T02:03:46Z

Expand Lemborexant with Stahl-sourced detail (with skepticism)

← Older revision		Revision as of 02:03, 16 May 2026
Line 1:		Line 1:
	{{MedTemplate		{{MedTemplate
	~~\| generic = Lemborexant~~		\| brand = Dayvigo
	\| brand = Dayvigo		\| classes = Dual orexin receptor antagonist (DORA)
	~~\| structure =~~		\| mechanism = Competitive antagonist at OX1R and OX2R. Faster receptor association/dissociation kinetics than suvorexant (~16 sec dissociation vs ~57 sec) hypothesized to support sleep onset, with sufficient duration for maintenance.
	\| classes = ~~Sedative-Hypnotic~~		\| uses = Insomnia (sleep onset and/or maintenance) in adults (FDA-approved Dec 2019)
	\| mechanism = ~~Dual orexin~~ receptor ~~antagonist~~		\| starting_dose = 5 mg PO at bedtime; may increase to 10 mg if inadequate
	\| uses =		\| preparations = 5 mg, 10 mg tablets
	\| starting_dose =		\| fda_max = 10 mg/d
	\| preparations =		\| routes = Oral
	\| fda_max =		\| onset = ~30 min
	\| routes =		\| duration = ~7-8 hours
	\| onset =		\| halflife = ~17-19 hours (longer than daridorexant)
	\| duration =		\| bioavailability = ~44%
	\| halflife =		\| pregnancy = Limited data; avoid
	\| bioavailability =		\| legal = Rx, Schedule IV (US)
	\| pregnancy =		\| intro = '''Lemborexant''' (brand name Dayvigo) is a dual orexin receptor antagonist (DORA) FDA-approved in December 2019 for insomnia in adults. Among DORAs, lemborexant has faster receptor association/dissociation kinetics than suvorexant — which is hypothesized to facilitate sleep onset while still maintaining adequate duration of antagonism for sleep maintenance. The 17-19 hour half-life can produce some next-day residual sedation in sensitive individuals.
	\| legal =
	\| intro =		DORAs broadly produce sleep that more closely resembles physiologic sleep architecture than GABAergic hypnotics, with reduced REM suppression. Side effect profile favorable compared to benzodiazepines, but sleep paralysis, sleep-related hallucinations, and complex sleep behaviors have been reported.
	~~\| pharmacokinetics =~~		\| pharmacodynamics= Competitive antagonism at OX1R (Ki ~6 nM) and OX2R (Ki ~3 nM). No clinically significant activity at other receptors.
	\| pharmacodynamics =		\| effects = Somnolence (next-day), headache, nightmares, abnormal dreams, sleep paralysis, hallucinations near sleep onset. Complex sleep behaviors class warning.
	~~\| indications =~~		\| interactions = <pharmaInteractions/>
	~~\| dosing~~ =
	\| effects =
	\| interactions = <pharmaInteractions/>
	~~\| pregnancy_details =~~
	~~\| monitoring =~~
	~~\| counseling =~~
	~~\| anecdotes =~~
	~~\| seealso =~~
	~~\| references =~~
	}}		}}


	[[Category:Anxiolytics & Sedative-Hypnotics]]		[[Category:Anxiolytics & Sedative-Hypnotics]]
	[[Category:Orexin Receptor Antagonists]]		[[Category:Orexin Receptor Antagonists]]
	[[Category:Sedative-Hypnotics]]		[[Category:Sedative-Hypnotics]]
			[[Category:Hypnotics]]
			[[Category:Orexin Antagonists]]

MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines

2026-05-14T15:06:53Z

Assign pharmacological categories from List_of_CNS-active_medicines

← Older revision		Revision as of 15:06, 14 May 2026
Line 31:		Line 31:
	}}		}}


			[[Category:Anxiolytics & Sedative-Hypnotics]]
			[[Category:Orexin Receptor Antagonists]]
	[[Category:Sedative-Hypnotics]]		[[Category:Sedative-Hypnotics]]

MDElliottMD: Pharmacopedia: add

2026-05-14T03:30:56Z

Pharmacopedia: add <pharmaInteractions/>

← Older revision		Revision as of 03:30, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	\| interactions =		\| interactions = <pharmaInteractions/>
	\| pregnancy_details =		\| pregnancy_details =
	\| monitoring =		\| monitoring =

MDElliottMD: Pharmacopedia: remove contraindications parameter

2026-05-14T02:40:38Z

Pharmacopedia: remove contraindications parameter

← Older revision		Revision as of 02:40, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	~~\| contraindications =~~
	\| interactions =		\| interactions =
	\| pregnancy_details =		\| pregnancy_details =

MDElliottMD: Added empty fda_max parameter to MedTemplate call

2026-05-13T02:32:43Z

Added empty fda_max parameter to MedTemplate call

← Older revision		Revision as of 02:32, 13 May 2026
Line 8:		Line 8:
	\| starting_dose =		\| starting_dose =
	\| preparations =		\| preparations =
			\| fda_max =
	\| routes =		\| routes =
	\| onset =		\| onset =
Line 32:		Line 33:

	[[Category:Sedative-Hypnotics]]		[[Category:Sedative-Hypnotics]]

MDElliottMD: Expand stub to full MedTemplate parameter set

2026-05-13T01:00:00Z

Expand stub to full MedTemplate parameter set

@@ Line 1: / Line 1: @@
 {{MedTemplate
-| generic           = Lemborexant
+| generic            = Lemborexant
-| brand             = Dayvigo
+| brand              = Dayvigo
-| classes           = Sedative-Hypnotic
+| structure          =
-| mechanism         = Dual orexin receptor antagonist
+| classes            = Sedative-Hypnotic
 }}
 [[Category:Sedative-Hypnotics]]